ClinicalTrials.gg
CompletedNCT03990688Updated Jun 9, 2021

A Study to Assess the Effect of AK3280 on Renal Function in Healthy Subjects

A Phase 1 interventional study of AK3280 and Placebo in Healthy, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in Sweden. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

AK3280 is being developed to further improve the long-term efficacy and tolerability of treatment options for patients with fibrotic disorders.This study will evaluate the effect of AK3280 treatment on renal function and safety, and the PK of AK3280 compared with placebo in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give full written for participation in the study.
  • Healthy male or female subject aged 18-45 years inclusive.
  • (BMI) ≥ 18.0 and ≤ 30.0 kg/m2。
  • Clinically normal medical history, physical findings, vital signs, and laboratory values at the time of screening, as judged by the Investigator in agreement with the Medical Monitor.
  • With normal renal function defined as mean plasma ≥80 mL/min/1.73 m2 at screening.
  • Male subjects and applicable female subjects must agree to use effective methods to prevent drug exposure of a partner and pregnancy.

Exclusion criteria

Exclusion Criteria:

  • History of allergy to iohexol or other contrast media, to iodine or to shellfish.
  • History of any disease or disorder or any other condition that in the opinion of the Investigator renders them unsuitable to participate in the study.
  • Regular use of any prescribed or non-prescribed medication within two weeks prior to the (first) administration of IMP.
  • Any significant elevation at screening or on Day -2 of liver or urinary or serum or plasma renal test results.
  • Subjects with poor venous access.
  • Subjects who have smoked cigarettes (including vapour cigarettes), cigars, and/or used nicotine-containing products within 3 months prior to their screening visit.
  • Positive screen for a drug of abuse or alcohol at screening or prior to administration of the IMP.
  • Subjects who have not abstained from caffeine-containing beverages or products from at least 48 hours prior to screening.
  • An abnormal diet within the 30 days prior to the first study drug dose.
  • Any use of protein powders, xanthine and/or taurine containing energy drinks within 48 hours prior to screening.
  • Blood donation (or corresponding blood loss) during the three months prior to screening.
  • Employees of the study unit or their family members, students who are working in the study unit, or family members of the Investigator or Sponsor.
  • Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    AK3280 (Cohort 1)

    Subjects in Cohort 1 are administered with an oral dose of 100 mg AK3280 b.i.d from Day 1 to Day 14.

    Drug: AK3280

  • Experimental
    AK3280 (Cohort 2)

    Subjects in Cohort 2 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 2 will be based on the emerging data from previous cohort.

    Drug: AK3280

  • Experimental
    AK3280 (Cohort 3)

    Subjects in Cohort 3 are orally administered with AK3280 q.d. or b.i.d from Day 1 to Day 14. The dose adjustment for Cohort 3 will be based on the emerging data from previous cohorts.

    Drug: AK3280

  • Placebo comparator
    Placebo

    For assessment of the Adverse Event (AE) profile, there are placebo controls in each dose cohort.

    Drug: Placebo

Interventions

  • DrugAK3280

    Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

  • DrugPlacebo

    Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral

06

What researchers measure

Primary outcomes

  1. Directly measured absolute glomerular filtration rate (mGFR) results.

    The effect of AK3280 treatment on GFR is measured by iohexol plasma clearance.

    Time frame: Days -1, 7, and 14.

  2. Change from baseline mGFR results.

    To compare the difference of effect of AK3280 treatment on GFR.

    Time frame: Days 7 and 14.

Secondary outcomes

  1. Frequency, intensity, and seriousness of Adverse Events (AEs)

    An AE can be any unfavorable and unintended sign (including an abnormal safety laboratory finding), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.

    Time frame: From Day -1 to Day 28.

  2. Change in blood renal function biomarkers

    Blood renal function biomarkers include cystatin C, beta-trace protein, p-myoglobin, etc.

    Time frame: Screening, Days -2, 7, 14, and 21.

  3. Change in urine renal function biomarkers

    Urine renal function biomarkers include electrolytes, albumin, alpha1-microglobulin, etc.

    Time frame: From Day -1 to Day 21.

  4. Maximum Observed Plasma Concentration (Cmax)

    The maximum observed plasma concentration of AK3280 and its major metabolite, AK3280-M2.

    Time frame: Days 1, 7, and 14.

  5. Concentration at the end of the dosing interval (Ctau)

    The concentration of AK3280 and its major metabolite, AK3280-M2, at the end of the dosing interval.

    Time frame: Days 1, 7, and 14.

  6. trough plasma concentration (Ctrough)

    The trough observed plasma concentration of AK3280 and its major metabolite, AK3280-M2.

    Time frame: Days 1, 7 and 14.

  7. trough plasma concentration (Ctrough)

    The trough observed plasma concentration of AK3280 and its major metabolite, AK3280-M2.

    Time frame: Days 1, 7, and 14.

  8. Area under the plasma concentration-time curve from time zero up to time (AUC 0-t)

    The area under the plasma concentration-time curve from time zero up to the last analytically quantifiable concentration of AK3280.

    Time frame: Days 1, 7, and 14.

07

Study locations

1 site
  • CTC Clinical Trial Consultants AB
    Uppsala, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Sep 2020, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2019
First posted
Jun 19, 2019
StartActual
Oct 3, 2019
Primary completionActual
Sep 9, 2020
CompletionActual
Sep 21, 2020
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03990688
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jun 19, 2019
Start date
Oct 3, 2019
Primary completion
Sep 9, 2020
Completion
Sep 21, 2020
Last update
Jun 9, 2021

Study contacts

Jimmy Gu
study director · info@arkbiosciences.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AK3280

Start the discussion